Stoke Therapeutics Yönetim
Yönetim kriter kontrolleri 3/4
Stoke Therapeutics CEO'su Ed Kaye, Oct2017 tarihinde atandı, in görev süresi 7.08 yıldır. in toplam yıllık tazminatı $ 3.53M olup, şirket hissesi ve opsiyonları dahil olmak üzere 17.7% maaş ve 82.3% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.051% ine doğrudan sahiptir ve bu hisseler $ 305.40K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.8 yıl ve 6.2 yıldır.
Anahtar bilgiler
Ed Kaye
İcra Kurulu Başkanı
US$3.5m
Toplam tazminat
| CEO maaş yüzdesi | 17.7% |
| CEO görev süresi | 7.1yrs |
| CEO sahipliği | 0.05% |
| Yönetim ortalama görev süresi | 3.8yrs |
| Yönetim Kurulu ortalama görev süresi | 6.2yrs |
Son yönetim güncellemeleri
Recent updates
Earnings Update: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Reported And Analysts Are Trimming Their Forecasts
Nov 08
Industry Analysts Just Made A Huge Upgrade To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Revenue Forecasts
Nov 06Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome
Sep 07We're Keeping An Eye On Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Jul 22Stoke Therapeutics' STK-001: A Potential Game-Changer For Dravet Syndrome
Jun 14It Looks Like Stoke Therapeutics, Inc.'s (NASDAQ:STOK) CEO May Expect Their Salary To Be Put Under The Microscope
May 30Stoke Therapeutics: Positive Dravet Data Sends Shares Soaring, One For The Watchlist
Apr 04Here's Why We're Watching Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Situation
Mar 21We're Keeping An Eye On Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Dec 07Party Time: Brokers Just Made Major Increases To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Earnings Forecasts
May 09Analysts Are Upgrading Stoke Therapeutics, Inc. (NASDAQ:STOK) After Its Latest Results
May 06Stoke Therapeutics (NASDAQ:STOK) Is In A Strong Position To Grow Its Business
May 02We're Interested To See How Stoke Therapeutics (NASDAQ:STOK) Uses Its Cash Hoard To Grow
Dec 13Companies Like Stoke Therapeutics (NASDAQ:STOK) Can Afford To Invest In Growth
Aug 14Stoke Therapeutics GAAP EPS of -$0.63 beats by $0.05, revenue of $3.2M beats by $0.18M
Aug 08We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Apr 29Stoke Therapeutics (NASDAQ:STOK) Is In A Good Position To Deliver On Growth Plans
Jan 13We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Sep 30We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely
Jun 16Stoke Therapeutics EPS misses by $0.02
May 10We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely
Mar 03CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$105m |
| Jun 30 2024 | n/a | n/a | -US$104m |
| Mar 31 2024 | n/a | n/a | -US$109m |
| Dec 31 2023 | US$4m | US$626k | -US$105m |
| Sep 30 2023 | n/a | n/a | -US$103m |
| Jun 30 2023 | n/a | n/a | -US$105m |
| Mar 31 2023 | n/a | n/a | -US$99m |
| Dec 31 2022 | US$6m | US$596k | -US$101m |
| Sep 30 2022 | n/a | n/a | -US$100m |
| Jun 30 2022 | n/a | n/a | -US$96m |
| Mar 31 2022 | n/a | n/a | -US$94m |
| Dec 31 2021 | US$9m | US$568k | -US$86m |
| Sep 30 2021 | n/a | n/a | -US$76m |
| Jun 30 2021 | n/a | n/a | -US$67m |
| Mar 31 2021 | n/a | n/a | -US$58m |
| Dec 31 2020 | US$5m | US$549k | -US$52m |
| Sep 30 2020 | n/a | n/a | -US$48m |
| Jun 30 2020 | n/a | n/a | -US$43m |
| Mar 31 2020 | n/a | n/a | -US$38m |
| Dec 31 2019 | US$668k | US$477k | -US$32m |
| Sep 30 2019 | n/a | n/a | -US$26m |
| Jun 30 2019 | n/a | n/a | -US$21m |
| Mar 31 2019 | n/a | n/a | -US$16m |
| Dec 31 2018 | US$1m | US$464k | -US$13m |
Tazminat ve Piyasa: Ed 'nin toplam tazminatı ($USD 3.53M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 2.24M ).
Tazminat ve Kazançlar: Ed 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Ed Kaye (75 yo)
7.1yrs
Görev süresi
US$3,533,210
Tazminat
Dr. Edward M. Kaye, also known as Ed, M.D., Ph.D. has been Special Regulatory and Scientific Advisor of Sarepta Therapeutics, Inc. since June 28, 2017. He serves as Independent Director at Avidity Bioscien...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Director | 7.1yrs | US$3.53m | 0.051% $ 305.4k | |
| Co-Founder & Independent Director | no data | US$198.33k | 0.76% $ 4.6m | |
| Chief Medical Officer | 7.1yrs | US$1.65m | 0.0047% $ 28.1k | |
| Co-Founder & Senior VP of Discovery Research | no data | Veri yok | Veri yok | |
| Chief Financial Officer | less than a year | Veri yok | Veri yok | |
| Head of Investor Relations | no data | Veri yok | Veri yok | |
| Corporate Secretary & General Counsel | 3.8yrs | Veri yok | 0.0049% $ 29.4k | |
| Chief Communications Officer | 3.8yrs | Veri yok | Veri yok | |
| Chief Human Resources Officer | 5.1yrs | Veri yok | Veri yok | |
| Senior VP of Quality & Chief Regulatory Affairs Officer | 5.9yrs | Veri yok | Veri yok | |
| Chief Commercial Officer | less than a year | Veri yok | Veri yok | |
| Chief Business Officer | less than a year | Veri yok | Veri yok |
3.8yrs
Ortalama Görev Süresi
52yo
Ortalama Yaş
Deneyimli Yönetim: STOK 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.8 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Director | 7.1yrs | US$3.53m | 0.051% $ 305.4k | |
| Co-Founder & Independent Director | 10.4yrs | US$198.33k | 0.76% $ 4.6m | |
| Independent Director | 9.3yrs | US$237.33k | 3.54% $ 21.2m | |
| Independent Director | 9.2yrs | US$198.33k | 0.034% $ 203.3k | |
| Independent Director | 1.2yrs | US$394.03k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$199.33k | 0% $ 0 | |
| Independent Director | 4.4yrs | US$206.83k | 0% $ 0 | |
| Independent Director | 5.4yrs | US$209.33k | 0% $ 0 | |
| Independent Chairman | 6.2yrs | US$211.83k | 0.060% $ 359.0k |
6.2yrs
Ortalama Görev Süresi
61yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: STOK 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.2 yıldır).